盘龙药业(002864) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥120,534,391.24, representing a 27.89% increase compared to ¥94,246,673.75 in the same period last year[8] - Net profit attributable to shareholders was ¥11,986,886.45, up 24.69% from ¥9,613,067.73 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached ¥10,489,539.40, reflecting a 27.67% increase from ¥8,215,885.68 in the previous year[8] - Basic earnings per share increased to ¥0.1383, a rise of 24.71% from ¥0.1109[8] - Total operating revenue for Q1 2019 reached ¥120,534,391.24, an increase of 28% compared to ¥94,246,673.75 in the same period last year[35] - Net profit for Q1 2019 was ¥11,986,886.45, representing a 25% increase from ¥9,613,067.73 in Q1 2018[36] - The total profit for the current period was ¥14,267,042.96, compared to ¥10,772,342.82 in the previous period, marking an increase of around 32.7%[40] Cash Flow - The net cash flow from operating activities surged by 160.00%, amounting to ¥9,613,393.35 compared to ¥3,697,480.38 in the same period last year[8] - Net cash flow from operating activities increased by 160.00% to ¥9,613,393.35, up from ¥3,697,480.38, mainly due to the growth in operating revenue[16] - The company reported cash inflows from operating activities totaling ¥148,079,261.81, compared to ¥101,777,615.07 in the previous period, which is an increase of about 45.4%[44] - The cash outflows from operating activities were ¥138,465,868.46, up from ¥98,080,134.69, indicating an increase of approximately 40.9%[44] - The company experienced a net cash outflow from investing activities of ¥19,579,010.68, compared to a larger outflow of ¥235,730,442.85 in the previous period[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥835,336,416.14, a 2.14% increase from ¥817,835,805.47 at the end of the previous year[8] - The company's total liabilities increased slightly to ¥211,751,946.93 from ¥206,238,222.71, reflecting ongoing operational commitments[27] - The total assets of the company as of March 31, 2019, amounted to ¥835,336,416.14, compared to ¥817,835,805.47 at the end of the previous year[26] - The company's total liabilities stood at ¥157,699,394.66, slightly up from ¥157,394,609.28 in the previous quarter[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,062[12] - The largest shareholder, Xie Xiaolin, holds 42.89% of the shares, totaling 37,171,000 shares[12] - The total equity attributable to shareholders reached ¥623,145,876.32, an increase from ¥610,837,403.90 at the end of 2018[33] Research and Development - Research and development expenses rose significantly by 109.58% to ¥1,718,105.72 from ¥819,771.55, attributed to payments made according to R&D progress[16] - Research and development expenses for Q1 2019 were ¥1,718,105.72, nearly double the ¥819,771.55 spent in Q1 2018, indicating a strong focus on innovation[35] Non-Recurring Gains and Losses - The company reported non-recurring gains of ¥1,497,347.05, which included government subsidies and investment management income[9] - The company reported a substantial increase in non-operating income, which surged by 4133.07% to ¥402,868.90 from ¥9,517.18, primarily due to government subsidies received[16] Inventory and Cash Management - The cash and cash equivalents decreased to ¥75,157,539.57 from ¥85,123,156.90, indicating a reduction in liquidity[25] - The company’s inventory increased to ¥45,008,378.78 from ¥39,902,963.79, suggesting a buildup in stock levels[25] - The company's cash and cash equivalents decreased to ¥60,004,324.06 from ¥73,544,910.18, a decline of about 18%[29] Other Financial Metrics - The company reported a gross profit margin of approximately 10% for Q1 2019, compared to 11% in the same quarter last year, reflecting increased costs[35] - The accounts receivable balance was ¥163,164,760.08, slightly down from ¥168,687,810.15, indicating improved collection efforts[29] Reporting Practices - The first quarter report was not audited, indicating that the figures may be subject to change upon final review[51] - The company has not applied new financial instrument standards or new revenue recognition standards, indicating stability in reporting practices[50]